Christobel Selecky, a director at ImmunityBio, Inc. (NASDAQ:IBRX), completed a sale of 25,000 shares of the companys common stock on February 23, 2026, at $10 per share, producing proceeds of $250,000.
That same day Selecky exercised stock options to obtain 25,000 additional shares at an exercise price of $2.98 per share, for a total exercise cost of $74,500. The options originated from a prior stock option award. After these transactions, Selecky directly owns 67,937 shares of ImmunityBio common stock.
The public share disposition was executed pursuant to a Rule 10b5-1 trading plan that Selecky adopted on June 12, 2025.
Seleckys sale occurred against a backdrop of pronounced share-price appreciation for ImmunityBio. The stock has advanced 281% over the past year and was trading at $11.54 at the time of the report, which places it close to its 52-week high of $12.28.
On valuation, InvestingPro analysis referenced in company disclosures indicates the stock appears overvalued relative to a Fair Value estimate of $9.85. The analysis and related financial health metrics are noted as available on the InvestingPro platform.
Separately, ImmunityBio reported meaningful commercial progress for its cancer treatment ANKTIVA. For full-year 2025, ANKTIVA generated $113 million in revenue, representing a 700% increase from the prior year. The fourth quarter contributed $38.3 million in net product revenue, a 20% increase from the third quarter.
The company has expanded distribution for ANKTIVA in Europe through a partnership with Accord Healthcare, covering 30 European countries. That arrangement follows a conditional marketing authorization from the European Commission, which allows ANKTIVA to be marketed in 33 countries. The therapy addresses an unmet need for patients with BCG-unresponsive non-muscle invasive bladder cancer.
ImmunityBio also entered distribution partnerships with Biopharma and Cigalah Healthcare to introduce ANKTIVA in Saudi Arabia and across the Middle East and North Africa region, with distribution expected soon.
Market reaction from at least one sell-side analyst was positive: H.C. Wainwright raised its price target on ImmunityBio to $15 and maintained a Buy rating.
Context and takeaway - The insider sale and simultaneous option exercise are documented under a pre-established trading plan. The companys commercial momentum for ANKTIVA and recent analyst support coincide with a stock price that InvestingPro flags as above its assessed Fair Value.